Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes

Key clinical point: Linagliptin seems to be safe even in older people with cardiovascular and renal risk, but it does not improve cardiovascular outcomes.

Major finding: There was no increased risk with linagliptin in the primary composite outcome of cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction, compared with placebo (12.4% vs.12.1%, respectively; HR, 1.02; P = .74).

Study details: Randomized, placebo-controlled trial in more than 6,000 patients with type 2 diabetes.

Disclosures: Boehringer Ingelheim, the maker of linagliptin, funded the study. The presenter disclosed honoraria, speaking fees, and grants from the company. A number of the investigators were employees of the company.

Citation:

REPORTING FROM ADA 2019